Allergy Immunotherapy Market By Allergen Type (Seasonal Allergens, Perennial Allergens), By Age Group (Children, Adults), By Type of Immunotherapy (Subcutaneous Immunotherapy (SCIT), Sublingual Immunotherapy (SLIT)), By Distribution Channel (Hospital Pharmacies, Online Pharmacies), And Region For 20

Allergy Immunotherapy Market Valuation – 2024-2031

In the Allergy Immunotherapy Market, many factors are driving such as allergies becoming increasingly common over the world. This can be attributable to a variety of causes, including lifestyle changes, greater exposure to toxins, and heredity. This increase in allergies translates to a larger population seeking treatment, boosting the market for immunotherapy, which provides a long-term remedy rather than simply managing symptoms. The market size surpass USD 2.08 Billion valued in 2023 to reach a valuation of around USD 3.87 Billion by 2031.

Growing awareness of immunotherapy’s efficacy is leading to increased adoption. Unlike drugs that just treat symptoms, immunotherapy retrains the immune system to tolerate allergens, lowering the severity of reactions and enhancing overall quality of life. This drive toward cures rather than just management is propelling the market forward. The rising demand for cost-effective and efficient allergy immunotherapy is enabling the market grow at a CAGR of 8.10% from 2024 to 2031.

Allergy Immunotherapy MarketDefinition/ Overview

Allergy immunotherapy, also known as desensitization or hypo-sensitization, is a medical treatment that aims to reduce the allergic response to certain allergens. This treatment consists of gradually administering increasing dosages of the allergen to the patient, either through subcutaneous injections (SCIT) or sublingual drops/tablets (SLIT). The goal is to induce immunological tolerance to the allergen, which will reduce the intensity of allergic symptoms over time. This therapy addresses underlying allergic disease mechanisms rather than only treating symptoms, making it a proactive approach to allergy management.

It is generally used to treat allergic rhinitis (hay fever), allergic asthma, conjunctivitis (eye allergy), and stinging insect allergies (such as bees and wasps). It is especially effective for people who do not respond well to traditional allergy drugs or who have severe adverse effects from them. Allergists use tests to identify specific allergies and then develop a personalized treatment strategy for each patient. The method typically begins with a build-up phase, in which allergen dosages are gradually raised, followed by a maintenance phase, which can last many years and involves the patient receiving constant doses to maintain tolerance.

Allergy immunotherapy looks optimistic, with continuing research attempting to improve its efficacy, safety, and ease. Advances in molecular allergology are paving the way for more precise and targeted therapeutics, such as peptide-based vaccinations and recombinant allergens, which could provide more effective and safer treatments. There is also considerable interest in developing combination therapies that combine immunotherapy with biologics or other immune-modulating medications.

Will Growing Awareness and Innovation Drive the Allergy Immunotherapy Market?

The allergy immunotherapy market is expanding rapidly, and increasing awareness among patients and healthcare providers about the benefits of immunotherapy over conventional therapies is leading to higher adoption rates. Patients are learning more about the long-term benefits of allergy immunotherapy, such as its ability to change the normal course of allergic disorders and provide long-term relief, as opposed to the transitory symptom relief provided by antihistamines and corticosteroids.

Also, healthcare providers recognize the value of early intervention with immunotherapy in preventing the advancement of allergy diseases, particularly in youngsters. This rising awareness is likely to drive up demand for these therapies and encourages more healthcare practitioners to recommend them.

Innovation is also an important driver of growth in the allergy immunotherapy industry. Advances in biotechnology and immunology are paving the way for new, more effective, and safer kinds of immunotherapy.

Furthermore, research into innovative delivery modalities, such as epicutaneous immunotherapy (EPIT), as well as the creation of next-generation allergen extracts and recombinant allergens, is broadening the range of treatment possibilities. These advancements not only improve immunotherapies’ efficacy and safety profiles but also make them more accessible and acceptable to a larger patient group.

Will Side Effects Impact the Growth of the Allergy Immunotherapy Market?

The allergy immunotherapy business, while its influence may be minimized by ongoing research in the sector. While allergy immunotherapy is generally safe, it can cause moderate local reactions like redness and swelling at the injection site, as well as more severe systemic events like anaphylaxis. These concerns may prevent some patients and healthcare providers from seeking immunotherapy, especially if they have a history of severe allergic responses. The necessity for constant medical supervision during the early stages of treatment, particularly with subcutaneous immunotherapy, can be viewed as a barrier to the general acceptance of these treatments.

However, the influence of side effects on market development is being mitigated through ongoing innovation and enhanced safety measures. Advances in allergen extract formulation and the development of more focused medicines, such as peptide-based vaccinations and recombinant allergens, aim to lessen the likelihood of adverse reactions.

The growing popularity of sublingual immunotherapy (SLIT) and epicutaneous immunotherapy (EPIT), which offer a higher safety profile and are more convenient for patients, is helping to alleviate worries about side effects. Enhanced patient education, as well as the application of tight safety requirements in clinical practice, help to make these medicines more safely administered. As these advancements take root, the negative impact of side effects on market growth is predicted to fade, allowing the industry to continue to grow steadily.

Category-Wise Acumens

Will Continuous Exposure of Patients Accelerate the Perennial Allergens Segment for the Allergy Immunotherapy Market?

The perennial allergens segment is expected to take over the allergy immunotherapy market, owing to patients’ continued exposure to these allergens and the chronic nature of linked illnesses. Dust mites, pet dander, mold spores, and certain indoor pollutants are perennial allergies that exist all year, as opposed to seasonal allergens like pollen. This continual exposure causes persistent allergy reactions, demanding long-term and consistent treatment plans.

The allergy immunotherapy market will be driven by continual exposure to perennial allergens. Patients endure persistent allergy symptoms because of their year-round exposure to allergens such as dust mites, pet dander, and mold spores. Allergy immunotherapy provides a long-term solution and can change the course of allergic illnesses. The ongoing need for efficient management of perennial allergies, together with increased knowledge and developments in treatment options, assures that this sector will continue to play an important role in driving market expansion.

Seasonal allergies may have the most rapid development potential. While seasonal allergies induced by pollen may not necessitate year-round therapy, their increasing frequency is producing a sizable patient population.

Will Diagnosis and Management of Allergies in Children Bolster Allergy Immunotherapy Market?

The children segment is likely to dominate the allergy immunotherapy market over the forecast period. Asthma, allergic rhinitis, and eczema are becoming more common among youngsters, necessitating the development of efficient long-term care options. Early intervention with allergy immunotherapy in children can slow the progression of allergic illnesses, potentially preventing more severe conditions later in life. Parents and healthcare providers are increasingly realizing the benefits of initiating immunotherapy early, which is driving up demand for these treatments in the juvenile population.

The emphasis on enhancing the quality of life for children with allergies fuels the need for more effective and long-lasting treatment alternatives. Immunotherapy not only alleviates symptoms but also reduces the overall medication burden, making it an appealing alternative for long-term treatment. Ongoing research and development initiatives aim to create more tailored and safer therapies for children, meeting their distinct physiological demands. This trend is encouraged by the rising occurrence of allergies in children, as well as modern pediatric care’s proactive commitment to addressing chronic illnesses from an early age.

Adults are more likely to have a lengthy history of allergies and need continuing treatment than children, who may outgrow specific sensitivity.

Gain Access into Allergy Immunotherapy Market Report Methodology

Country/Region-wise Acumens

Will Increasing Infrastructure Benefits Boom the Growth of the Allergy Immunotherapy Market in the North America?

North America dominates the allergy immunotherapy business. This region has a well-established healthcare infrastructure that includes cutting-edge medical facilities, substantial research and development skills, and a solid regulatory framework. These characteristics aid in the development and uptake of novel allergy immunotherapy treatments, ensuring that new therapies may easily navigate regulatory procedures and reach patients. Furthermore, the region’s extensive network of healthcare providers and allergy experts ensures widespread access to immunotherapy treatments, which promotes market growth.

Furthermore, the rising frequency of allergic disorders in North America, notably allergic rhinitis and asthma, emphasizes the need for effective treatments like allergy immunotherapy. As patients and healthcare providers become more aware of the benefits of immunotherapy over traditional treatments, there is a greater desire to use these advanced therapies.

Collaborations between academic institutions, pharmaceutical companies, and healthcare providers in North America help to promote allergy immunotherapy research and development, promoting innovation and market expansion. Overall, the combination of strong infrastructure, regulatory support, and rising illness prevalence places North America as an important region for the allergy immunotherapy market.

Will Increase in Healthcare Expenditure Drive the Allergy Immunotherapy Market in Asia Pacific?

The Asia-Pacific region has the potential for the most rapid growth in the allergy immunotherapy market. As the Asia Pacific region experiences economic expansion and urbanization, healthcare spending rises in response, driven by improved access to healthcare services, rising incomes, and higher awareness of chronic disorders, including allergies. This trend is especially visible in countries such as China, India, and Japan, where governments are investing in healthcare infrastructure and extending insurance coverage, increasing access to modern therapies like allergy immunotherapy. The expanding middle-class population in these countries is also ready to spend more on healthcare, driving up demand for effective allergy treatments.

Furthermore, the rising prevalence of allergic illnesses in Asia Pacific, due to causes such as urban air pollution, changing food patterns, and exposure to new allergens, emphasizes the importance of comprehensive allergy management measures. Allergy immunotherapy is a promising approach that provides long-term comfort while potentially altering the underlying immune response to allergens.

As healthcare professionals and consumers become more aware of the benefits of immunotherapy, combined with advances in treatment accessibility and affordability, the Asia Pacific allergy immunotherapy market is expected to expand significantly. Collaborations between global pharmaceutical corporations and local healthcare professionals to produce specialized medicines for the region’s diverse population are also projected to fuel market growth in Asia Pacific.

Competitive Landscape

The allergy immunotherapy market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions, and political support.

The organizations are focusing on innovating their product line to serve the vast population in diverse regions. Some of the prominent players operating in the allergy immunotherapy market include

ALK-Abelló A/S, Stallergenes Greer plc, Allergy Therapeutics plc, Merck & Co. Inc. (known as MSD outside of the United States and Canada), Aimmune Therapeutics Inc., DBV Technologies SA, HAL Allergy Group, Biomay AG, Circassia Pharmaceuticals plc, Immunomic Therapeutics Inc., Anergis, ASIT Biotech, Adamis Pharmaceuticals Corporation

Latest Developments

• In January 2024, Inimmune Corporation (Inimmune) and Intrommune Therapeutics, Inc. (Intrommune), two clinical-stage immunotherapeutic companies, announced a collaboration to develop a novel oral mucosal allergy immunotherapy for treating peanut allergy.
• In October 2023, ALK reported the successful completion of Itulatek’s phase 3 trial for treating allergy rhinoconjunctivitis caused by tree pollen.
• In January 2023, HollisterStier Allergy launched its latest product innovation, Ultrafiltered Dog, in the allergy market. The product is excellent for diagnosing and treating dog-sensitive patients.
• In October 2022, Allergy Partners, a single specialty allergy practice group, partnered with Aimmune Therapeutics to offer Palforzia, an oral immunotherapy directly to patients.
• In June 2022, ALK launched a phase clinical study in North America for a new sublingual tablet to treat peanut allergy.

Report Scope

Research Methodology of Market Research

To know more about the Research Methodology and other aspects of the research study, kindly get in touch with our .

Reasons to Purchase this Report

• Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors• Provision of market value (USD Billion) data for each segment and sub-segment• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions and acquisitions in the past five years of companies profiled• Extensive company profiles comprising of company overview, company insights, product benchmarking and SWOT analysis for the major market players• The current as well as the future market outlook of the industry with respect to recent developments (which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions• Includes an in-depth analysis of the market of various perspectives through Porter’s five forces analysis• Provides insight into the market through Value Chain• Market dynamics scenario, along with growth opportunities of the market in the years to come• 6-month post-sales analyst support

Customization of the Report

• In case of any please connect with our sales team, who will ensure that your requirements are met.